Dr. Jianjun Wei (Joint School of Nanoscience and Nanoengineering) received new funding from the National Science Foundation for the project “3i Nano – A Point-of-Care Biosensor for Disease Diagnostics and Analysis.”
For many years, cardiovascular disease (CVD) has been diagnosed and tested in central laboratories, which may take several hours to days. This is one of major factors resulting in low survival rates and high treatment cost. Early detection is the key, not only for CVD patient survival, but also saving cost.
This is particularly true for the rupture of atherosclerotic plaque, such as endothelial dysfunction, inflammation, oxidative stress, proteolysis, and thrombosis. Biomarkers of CVD have been found to be very important tools for early diagnosis, because they serve as hallmarks for the physiological status of a cell at a given time and change during the disease process.
This proposal describes an investigation to determine the readiness to transition a point-of-care (POC) biosensor technology developed by a current NSF fund to a commercially viable product. The POC technology aims to achieve rapid detection of protein biomarkers of CVD at an early stage or acute attack. This project will map out a strategy for taking such technology to the next technical readiness level (TRL) by incorporating the recent advances into currently available portable commercial off-the-shelf (COTS) components.
The results of this project will provide first-hand evidence and data in both technology and market, that we can use to transform the current technology into a device, which will be lucrative in the medical industry.